| Literature DB >> 23650508 |
Binfeng He1, Jianchun Wang, Guisheng Qian, Mingdong Hu, Xinming Qu, Zhenghua Wei, Jin Li, Yan Chen, Huaping Chen, Qiquan Zhou, Guansong Wang.
Abstract
The syndrome of high-altitude de-acclimatization commonly takes place after long-term exposure to high altitudes upon return to low altitudes. The syndrome severely affects the returnee's quality of life. However, little attention has been paid to careful characterization of the syndrome and their underlying mechanisms. Male subjects from Chongqing (n = 67, 180 m) and Kunming (n = 70, 1800 m) visited a high-altitude area (3650 m) about 6 months and then returned to low-altitude. After they came back, all subjects were evaluated for high-altitude de-acclimatization syndrome on the 3(rd), 50(th), and 100(th). Symptom scores, routine blood and blood gas tests, and myocardial zymograms assay were used for observation their syndrome. The results showed that the incidence and severity of symptoms had decreased markedly on the 50(th) and 100(th) days, compared with the 3(rd) day. The symptom scores and incidence of different symptoms were lower among subjects returning to Kunming than among those returning to Chongqing. On the 3(rd) day, RBC, Hb, Hct, CK, CK-MB, and LDH values were significantly lower than values recorded at high altitudes, but they were higher than baseline values. On the 50(th) day, these values were not different from baseline values, but LDH levels did not return to baseline until the 100(th) day. These data show that, subjects who suffered high-altitude de-acclimatization syndrome, the recovery fully processes takes a long time (≥ 100(th) days). The appearance of the syndrome is found to be related to the changes in RBC, Hb, Hct, CK, CK-MB, and LDH levels, which should be caused by reoxygenation after hypoxia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23650508 PMCID: PMC3641122 DOI: 10.1371/journal.pone.0062072
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Symptom scores.
Data are presented as mean ± SD. *P<0.05, relative to the Chongqing group. ^P<0.05, relative to the 3rd day, # P<0.05, relative to the 50th day.
Figure 2Rates of change in symptom scores.
Data are presented as mean ± SD. Symptom scores recorded on the 3rd day after return to low-altitude areas served as baseline values. Rate of change 1 = (score on 50th day-score on 3rd day)/score on 3rd day×100%; rate of change 2 = (score on 100th day-score on 3rd day)/score on 3rd day×100%. Rates of change 1 and 2 showed no significant difference between the Chongqing and Kunming groups (P>0.05).
Incidence of symptoms of subjects after returning to Chongqing or Kunming after visiting high altitudes.
| Chongqing group (n = 67) | Kunming group (n = 70) | |||||
| Symptoms | 3rd day | 50th day | 100th day | 3rd day | 50th day | 100th day |
| Fatigue | 49 (73.13%) | 27 (40.29%)# | 8 (11.94%)& | 35 (50.00%) | 19 (27.14%)# | 6 (8.57%)& |
| Sleepiness | 48 (71.64%)* | 22 (32.83%)# | 9 (13.43%)& | 33 (47.14%) | 20 (28.57%)# | 11 (15.71%) |
| Insomnia | 29 (43.28%)* | 23 (34.32%)* | 9 (13.43%)& | 19 (27.14%) | 13 (18.57%) | 8 (11.42%) |
| Unresponsiveness | 31 (46.26%)* | 10 (14.92%)*# | 5 (7.46%) | 11 (15.71%) | 8 (11.42%) | 3 (4.28%) |
| Memory loss | 31 (46.26%)* | 20 (29.85%) | 10 (14.92%)& | 22 (31.42%) | 18 (25.71%) | 9 (12.85%)& |
| Agitation | 30 (44.77%)* | 24 (35.82%) | 12 (17.91%)& | 20 (28.57%) | 12 (17.14%) | 7 (10.00%) |
| Headache | 36 (53.73%)* | 27 (40.29%)* | 14 (20.89%)*& | 20 (28.57%) | 12 (17.14%) | 6 (8.57%) |
| Dizziness | 49 (73.13%)* | 27 (40.29%)# | 23 (17.91%) | 35 (50.00%) | 26 (37.14%) | 16 (22.85%) |
| Throat pain or discomfort | 28 (41.79%)* | 14 (20.89%)# | 7 (10.44%) | 15 (21.42%) | 8 (11.42%) | 4 (5.71%)& |
| Coughing | 49 (73.13%)* | 30 (44.76%)*# | 21 (31.34%)* | 37 (52.85%) | 18 (14.28%)# | 6 (8.57%) |
| Expectoration | 31 (46.26%) | 16 (23.88%)# | 8 (26.86%) | 35 (50.00%) | 8 (11.42%)# | 5 (7.14%) |
| Chest tightness | 37 (55.22%)* | 23 (34.32%)*# | 10 (14.92%)& | 17 (24.28%) | 10 (14.28%) | 6 (8.57%) |
| Flustering | 41 (61.19%)* | 25 (37.31%)*# | 18 (26.86%)* | 25 (35.71%) | 13 (18.57%)# | 5 (7.14%)& |
| Increased appetite | 31 (46.26%) | 11 (16.41%)# | 3(4.47%)& | 22 (31.42%) | 8 (11.42%)# | 1 (1.42%)& |
| Decreased appetite | 27 (40.29%)* | 17 (25.37%)*# | 5 (7.46%)& | 17 (24.28%) | 10 (14.28%) | 4 (5.71%) |
| Constipation | 22 (32.83%) | 8 (11.94%)# | 1 (1.49%)& | 19 (27.14%) | 6 (8.57%) | 0 (0.00%)& |
| Diarrhea | 18 (26.86%) | 8 (11.94%)# | 1 (1.49%)& | 13 (18.57%) | 6 (8.57%) | 1 (1.42%) |
| Abdominal distention | 44 (66.67%)* | 28 (41.79%) | 20 (29.85%)& | 32 (45.71%) | 20 (28.57%)# | 6 (8.57%)& |
| Abdominal pain | 40 (59.70%) | 29 (43.28%)# | 13 (19.40%) | 31 (44.28%) | 21 (30.00%) | 9 (12.85%)& |
| Lumbago | 29 (43.28%)* | 14 (20.89%)*# | 10 (14.92%) | 10 (14.28%) | 4 (5.71%) | 4 (5.71%) |
| Arthralgia | 39 (58.20%)* | 15 (22.38%)*# | 11 (16.41%) | 18 (25.71%) | 7 (10.00%) | 5 (7.14%) |
Data are given as the number (%). * P<0.05 relative to the Kunming group, # P<0.05, relative to 3rd day values, & P<0.05, relative to 50th day values.
pH, PaO2, PaCO2, and SaO2 of subjects after returning to Chongqing.
| HDAS group | Control group | |
|
|
|
|
| pH | 7.39±0.01 | 7.39±0.03 |
| PaO2 (hPa) | 126.97±5.59 | 128.37±5.26 |
| PaCO2 (hPa) | 49.38±2.90 | 49.46±2.52 |
| SaO2 (%) | 97.36±0.53 | 98.36±0.46 |
|
|
|
|
| pH | 7.45±0.06 | 7.41±0.03 |
| PaO2 (hPa) | 81.58±4.33*△ | 129.12±4.22 |
| PaCO2 (hPa) | 35.00±4.41*△ | 51.28±3.27 |
| SaO2 (%) | 87.32±1.45*△ | 97.85±0.89 |
|
|
|
|
| pH | 7.40±0.03 | 7.38±0.04 |
| PaO2 (hPa) | 125.84±3.27& | 128.78±4.38 |
| PaCO2 (hPa) | 46.85±1.94& | 51.79±3.83 |
| SaO2 (%) | 96.78±0.85& | 97.45±0.63 |
Data are given as the mean ± SD. * P<0.05, relative to baseline, & P<0.05, relative to high altitude values recorded at 6 months, △ P<0.05, relative to the control group
pH, PaO2, PaCO2, and SaO2 of subjects after returning to Kunming.
| HDAS group | Control group | |
|
|
|
|
| pH | 7.40±0.02 | 7.42±0.04 |
| PaO2 (hPa) | 119.76±6.49 | 119.49±5.26 |
| PaCO2 (hPa) | 45.39±2.75 | 46.51±3.52 |
| SaO2 (%) | 95.36±0.83 | 96.11±0.59 |
|
|
|
|
| pH | 7.43±0.09 | 7.39±0.05 |
| PaO2 (hPa) | 88.87±4.33*△ | 121.12±6.22 |
| PaCO2 (hPa) | 37.45±5.47△ | 47.32±2.27 |
| SaO2 (%) | 89.32±1.32*△ | 94.85±1.23 |
|
|
|
|
| pH | 7.41±0.07 | 7.40±0.06 |
| PaO2 (hPa) | 120.10±7.48& | 12.35±4.38 |
| PaCO2 (hPa) | 42.73±4.13 | 44.78±3.98 |
| SaO2 (%) | 94.42±1.02& | 95.25±0.98 |
Data are given as the mean ± SD. * P<0.05, relative to baseline, & P<0.05, relative to high altitude values, △ P<0.05, relative to the control group
Whole blood test results of subjects after returning to Chongqing.
| Group | Parameter | Baseline | High altitudes 6 months | 3rd day | 50th day | 100th day |
| HDAS group (n = 67). | RBC (×1012) | 4.90±0.23 | 5.89±0.57*△ | 5.43±0.62*&△ | 4.97±0.38&# | 4.91±0.30&# |
| Hb (g/L) | 143.70±11.14 | 177.94±13.02*△ | 168.36±9.32*&△ | 156.85±8.87&#△ | 146.73±8.45&# | |
| Hct (%) | 40.19±2.48 | 55.69±4.03*△ | 47.11±3.02*&△ | 41.46±2.71& | 42.79±2.54& | |
| MCV (fL) | 81.96±3.58 | 93.29±6.52*△ | 91.72±5.72*△ | 90.64±5.51* | 85.27±4.26&#^ | |
| MCH (pg) | 31.35±1.70 | 30.36±2.51 | 32.68±2.69*&△ | 31.23±2.09&# | 32.02±1.21&# | |
| RDW (%) | 13.96±0.46 | 13.97±0.92 | 13.61±0.98& | 11.76±0.77*&#△ | 13.62±0.48̂△ | |
| WBC (×109) | 5.84±0.96 | 6.07±1.64 | 7.47±1.63*&△ | 5.90±1.85# | 5.61±1.22# | |
| Neu (%) | 50.99±6.86 | 53.71±8.67 | 63.09±6.41*&△ | 54.24±8.35# | 54.49±7.17# | |
| Control group (n = 92) | RBC (×1012) | 4.85±0.37 | 4.97±0.29 | 4.79±0.34 | 4.80±0.16 | 4.90±0.18 |
| Hb (g/L) | 143.53±6.92 | 149.26±7.15 | 147.40±6.44 | 147.33±6.12 | 145.26±6.61 | |
| Hct (%) | 41.74±2.92 | 40.97±3.38 | 41.97±2.93 | 41.52±3.34 | 40.70±3.06 | |
| MCV (fL) | 83.96±3.17 | 84.74±4.33 | 85.16±3.73 | 85.62±3.47 | 84.70±3.05 | |
| MCH (pg) | 30.25±1.99 | 29.30±1.66 | 29.98±1.53 | 30.08±1.44 | 30.19±1.30 | |
| RDW (%) | 14.09±0.39 | 13.95±0.60 | 13.85±0.71 | 14.08±0.77 | 13.99±0.68 | |
| WBC (×109) | 5.98±0.98 | 5.75±0.86 | 5.81±0.73 | 5.90±0.91 | 5.87±0.79 | |
| Neu (%) | 53.58±6.18 | 55.72±3.24 | 55.46±3.34 | 56.77±3.31 | 56.48±3.52 |
Data are given as the mean ± SD. RBC = red blood cell, Hb = hemoglobin, Hct = hematocrit, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, RDW = red blood cell volume distribution width, WBC = white blood cell, Neu = neutrophil. * P<0.05, relative to baseline, & P<0.05, relative to high altitude values, # P<0.05, relative to 3rd day values, ^P<0.05, relative to 50th day values, △ P<0.05, relative to the control group.
Whole blood test results of subjects after returning to Kunming.
| Group | Parameter | Baseline | High altitudes 6 months | 3rd day | 50th day | 100th day |
| HDAS group (n = 70) | RBC (×1012) | 5.15±0.43 | 5.69±0.32*△ | 5.54 ±0.50*&△ | 5.23±0.31&# | 5.08±0.38&# |
| Hb (g/L) | 151.65±9.31 | 180.50±15.90*△ | 169.43±11.12*&△ | 157.27±8.51&# | 149.85±8.90&# | |
| Hct (%) | 43.42±2.71 | 57.89±4.16*△ | 49.13±3.10*&△ | 44.18±3.30& | 43.92±2.25& | |
| MCV (fL) | 89.07±4.02 | 95.59±12.14* | 88.82±5.49& | 90.30±5.16& | 90.56±4.37& | |
| MCH (pg) | 30.48±1.79 | 35.58±3.14*△ | 32.00±2.92*&△ | 32.70±2.35*&△ | 31.76±1.92*&△ | |
| RDW (%) | 13.48±0.81 | 14.14±1.70 | 12.91±0.58*&△ | 13.00±0.93*& | 13.08±0.69*& | |
| WBC (×109) | 5.47±1.07 | 6.73±0.58△ | 7.14±0.46*&△ | 5.64±0.78&# | 5.22±0.93&# | |
| Neu (%) | 52.89±3.27 | 56.80±3.53 | 65.80±3.27*△ | 54.60±6.36# | 53.77±7.76# | |
| Control group (n = 87) | RBC (×1012) | 5.12±0.24 | 5.19±0.55 | 5.18±0.15 | 5.13±0.30 | 5.09±0.24 |
| Hb (g/L) | 153.40±7.92 | 154.94±6.08 | 151.84±9.13 | 154.75±4.31 | 150.68±9.07 | |
| Hct (%) | 43.34±2.56 | 42.48±2.87 | 43.46±2.43 | 43.44±2.77 | 42.90±2.29 | |
| MCV (fL) | 88.95±2.58 | 90.18±2.76 | 88.60±2.93 | 89.45±2.88 | 89.33±3.03 | |
| MCH (pg) | 30.16±2.09 | 31.12±1.28 | 29.73±2.01 | 30.30±2.17 | 30.55±1.39 | |
| RDW (%) | 13.46±0.91 | 13.36±0.70 | 13.41±0.65 | 13.48±1.00 | 13.32±0.80 | |
| WBC (×109) | 5.30±1.06 | 5.53±1.07 | 5.50±1.02 | 5.51±1.09 | 5.52±1.00 | |
| Neu (%) | 55.36±8.81 | 55.78±4.04 | 57.63±5.46 | 56.63±5.58 | 57.14±4.05 |
Data are given as the mean ± SD. RBC = red blood cell, Hb = hemoglobin, Hct = hematocrit, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, RDW = red blood cell volume distribution width, WBC = white blood cell, Neu = neutrophil. * P<0.05, relative to baseline, & P<0.05, relative to high altitude values, # P<0.05, relative to 3rd day values, ^P<0.05, relative to 50th day values, △ P<0.05, relative to the control group.
Figure 3Rates of change of RBC, Hb, and Hct.
Data are presented as mean ± SD. The rate of change of (A) RBC, (B) Hb, and (C) Hct. Values recorded in subjects at high altitudes served as a baseline. Rate of change 1 = (value on the 3rd day-value at high altitudes)/value at high altitudes×100%; rate of change 2 = (value on the 50th day-value at high altitudes)/value at high altitudes×100%, rate of change 3 = (value on the 100th day-value at high altitudes)/value at high altitudes×100%. Rates of change 1, 2, and 3 showed no significant differences between the Chongqing and Kunming groups (P>0.05).
Serum CK, CK-MB, and LDH of subjects after returning to Chongqing.
| Group | Parameter | Baseline | High altitudes 6 months | 3rd day | 50th day | 100th day |
| HDAS group (n = 67) | CK (IU/L) | 88.70±17.77 | 92.90±21.80 | 121.73±28.91*&△ | 97.57±21.91# | 94.02±18.20# |
| CK-MB (IU/L) | 16.30±2.62 | 16.50±3.59 | 21.91±3.18*&△ | 17.63±3.23# | 15.80±4.61# | |
| LDH (IU/L) | 147.06±22.28 | 151.98±34.40 | 200.33±26.06*&△ | 177.18±31.87*&#△ | 146.38±22.52#^ | |
| Control group (n = 92) | CK (IU/L) | 87.50±16.09 | 91.37±17.95 | 88.62±12.11 | 91.50±18.64 | 89.87±11.36 |
| CK-MB (IU/L) | 15.95±2.20 | 14.76±2.25 | 16.33±1.69 | 15.74±1.91 | 14.92±2.49 | |
| LDH (IU/L) | 146.53±19.15 | 151.16±16.95 | 142.64±17.57 | 152.69±18.17 | 149.14±21.56 |
Data are given as the mean ± SD. CK = creatine kinase, CK-MB = creatine kinase–MB, LDH = lactate dehydrogenase. * P<0.05, relative to baseline, & P<0.05, relative to high altitude values, # P<0.05, relative to 3rd day values, ^P<0.05, relative to 50th day values, △ P<0.05, relative to the control group.
Serum CK, CK-MB, and LDH of subjects after returning to Kunming.
| Group | Parameter | Baseline | High altitudes 6 months | 3rd day | 50th day | 100th day |
| HDAS group (n = 70) | CK (IU/L) | 88.52±14.30 | 90.63±20.70 | 119.00±15.42*&△ | 96.36±18.96# | 90.36±14.37# |
| CK-MB (IU/L) | 15.04±1.38 | 16.07±3.16 | 21.41±3.26*&△ | 17.12±3.03#△ | 16.39±3.33# | |
| LDH (IU/L) | 150.79±20.99 | 153.44±26.42 | 198.02±35.55*&△ | 176.41±26.94*&#△ | 149.10±15.29#^ | |
| Control group (n = 87) | CK (IU/L) | 90.96±21.89 | 88.19±21.06 | 90.74±18.24 | 86.03±14.74 | 93.15±15.55 |
| CK-MB (IU/L) | 15.09±2.48 | 15.50±2.35 | 15.71±3.36 | 15.53±2.94 | 14.90±3.04 | |
| LDH (IU/L) | 148.72±17.78 | 150.16±20.56 | 147.29±18.50 | 152.73±18.93 | 150.75±19.20 |
Data are given as the mean ± SD. CK = creatine kinase, CK-MB = creatine kinase–MB, LDH = lactate dehydrogenase. * P<0.05, relative to baseline, & P<0.05, relative to high altitude values, # P<0.05, relative to 3rd day values, ^P<0.05, relative to 50th day values, △ P<0.05, relative to the control group.
Figure 4Rates of change of CK, CK-MB, and LDH.
Data are presented as mean ± SD. The rate of change rate of (A) CK, (B) CK-MB, (C) LDH. Values recorded in subjects at high altitudes served as the baseline. Rate of change 1 = (value on 3rd day-value at high altitudes)/value at high altitudes×100%; rate of change 2 = (value on 50th day-value at high altitudes)/value at high altitudes×100%; rate of change 3 = (value at 100th day-value at high altitudes)/value at high altitudes×100%. Rates of change 1, 2, and 3 were not significantly different between the Chongqing group and Kunming group (P>0.05).
Classification and scoring criteria of the symptoms of high-altitude de-acclimatization syndrome.
| Classification | Judgment standards | Scoring standards |
| ± | Mild symptoms with no impact on daily life | 0 |
| + | Mild symptoms with slight impact on daily life, ameliorated after drug regimen | 1 |
| ++ | Severe symptoms affect daily life, somewhat alleviated after drug regimen | 2 |
| +++ | Severe symptoms affect daily life, no significant relief after drug regimen | 3 |
Grading of high-altitude altitude de-acclimatization syndrome.
| Classification | Diagnostic criteria |
| Almost no reaction (±) | Suspected symptoms (±) or 0–5 total points |
| Mild reaction (+) | Slight symptoms (+) or 6–15 total points |
| Moderate reaction (++) | More serious symptoms (++) or 16–25 total points |
| Severe reaction (+++) | Very serious symptoms (+++) or 26 or more total points |